Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0376358 (prostate cancer)
 59,338 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Elucidating oncogenic pathways in prostate cancer is an arduous task. In this issue of Cancer Cell, Yu and colleagues show that repression of Adrenergic Receptor Beta-2 gene expression by Enhancer of Zeste 2 results in acquisition of transforming activities. It is interesting that these activities point to a role for GTPases as important regulators of transformation in prostate cancer cells. They further implicate epithelial-mesenchymal transition as a biologic end point in this process. Overall, on the basis of their findings, the authors nominate a novel oncogenic pathway for prostate cancer that deserves critical thought and attention.
 ...
PMID:Suppression of tumor suppressors in prostate cancer: the emergence of a novel oncogenic pathway. 1799 46

The Polycomb group (PcG) protein EZH2 possesses oncogenic properties for which the underlying mechanism is unclear. We integrated in vitro cell line, in vivo tumor profiling, and genome-wide location data to nominate key targets of EZH2. One of the candidates identified was ADRB2 (Adrenergic Receptor, Beta-2), a critical mediator of beta-adrenergic signaling. EZH2 is recruited to the ADRB2 promoter and represses ADRB2 expression. ADRB2 inhibition confers cell invasion and transforms benign prostate epithelial cells, whereas ADRB2 overexpression counteracts EZH2-mediated oncogenesis. ADRB2 is underexpressed in metastatic prostate cancer, and clinically localized tumors that express lower levels of ADRB2 exhibit a poor prognosis. Taken together, we demonstrate the power of integrating multiple diverse genomic data to decipher targets of disease-related genes.
 ...
PMID:Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. 1799 41